1. Scrip
  2. >>Business
  3. >>Deals

Venture Affairs Of The Heart

 
• By Andrea Mancini

A survey of the fundraising activities of 183 private cardiovascular medtech, biopharma, and diagnostics companies from 2010 through April 2015 revealed that by 2014, following two years of waning venture investments, the group had raised less than half the capital secured in 2010. And although the average raised per round was roughly the same, the volume of deals was significantly higher in 2010.

Reimbursement risks and unpredictable regulatory paths have had a lingering negative impact on venture investments in medtech companies. This seems particularly true in the medtech-dominant cardiovascular space, where such funding has been on a steady decline now for several years. The exit of choice for most closely held cardiovascular innovators has undoubtedly been acquisition by bigger players, with a much smaller number making public debuts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Another CRL Prompts Questions About Regeneron’s Regulatory Operations

 
• By Alaric DeArment

CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.